Amgen and Daiichi Sankyo announce agreement to commercialize biosimilars in Japan
- Details
- Category: Daiichi Sankyo
Amgen (NASDAQ:AMGN) and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo; TSE 4568) today announced the execution of an exclusive agreement to commercialize nine biosimilars in Japan. The deal includes several biosimilars in late stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab.
Boehringer Ingelheim and Lilly announce clinical trial collaboration in metastatic breast cancer
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of BI 836845, Boehringer Ingelheim's insulin-like growth factor (IGF)-1/IGF-2 ligand neutralising antibody, in combination with abemaciclib (LY2835219), Lilly’s cyclin-dependent kinase (CDK) 4 and 6 inhibitor, in patients diagnosed with HR+/HER2- mBC.
FDA approves first and only single monthly injection for a PCSK9 inhibitor
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha® (evolocumab) PushtronexTM system (on-body infusor with prefilled cartridge), a new, monthly single-dose administration option.
Merck and Pfizer initiate Phase III trial to evaluate Avelumab as first-line treatment for ovarian cancer
- Details
- Category: Pfizer
Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) have announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of avelumab* in combination with, and/or as follow-on (maintenance) treatment to, platinum-based chemotherapy in patients with locally advanced or metastatic disease (Stage III or Stage IV) with previously untreated epithelial ovarian cancer.
Merck commits €1.5 million to the Grant for Fertility Innovation (GFI) for 2016/17
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced it would continue to support the advancement of medical science in the field of fertility through the Grant for Fertility Innovation (GFI) program by awarding grants totalling €1.5 million in 2016/17.
Sanofi Pasteur signs research agreement for Zika vaccine
- Details
- Category: Sanofi
Sanofi and its vaccines global business unit Sanofi Pasteur announced today a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research (WRAIR) on the co-development of a Zika vaccine candidate.
Bristol-Myers Squibb acquires Cormorant Pharmaceuticals
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a private, Stockholm, Sweden-based pharmaceutical company focused on the development of therapies for cancer and rare diseases.
More Pharma News ...
- Novo Nordisk and Aarhus University team up on world-class talents
- AstraZeneca enters licensing agreements with LEO Pharma in skin diseases
- Bristol-Myers Squibb and PsiOxus Therapeutics announce immuno-oncology clinical collaboration
- Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor
- New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
- Pfizer completes acquisition of Anacor
- Amgen Golden Ticket winners receive lab space and other benefits at QB3@953